Jun 07, 2023 / 12:30PM GMT
Akash Tewari - Jefferies LLC, Research Division - Equity Analyst
Good morning, everyone. For those who just got back from ASCO, I feel sorry for you. I'm exhausted as well. But this is day 1 of our Jefferies Healthcare Conference, something that I am just really excited about, and I have the pleasure of hosting Regeneron, and I'm going to hand it off to Ryan for some brief introductions and forward-looking statements, and then we'll get into some questions.
Ryan Crowe - Regeneron Pharmaceuticals, Inc. - VP of IR
Thanks, Akash, and thanks for having us here at the Jefferies conference. It's always well attended, and I'm excited to be here. I'll start off with some forward-looking statement disclosures. I'd like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron's SEC
Regeneron Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers